Kidney dialysis drug study pulled before it started

NCT ID NCT02695641

Terminated Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to see how a low dose of bevacizumab (Avastin) behaves in the body and whether it safely lowers a certain protein (VEGF-A) in people with kidney failure on dialysis. The goal was to gather information for a future trial on preventing dialysis access failure. However, the study was withdrawn before any participants were enrolled, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin)
What this could lead to: If successful, this could help design a future trial to prevent dialysis access failure.
What could go wrong: The study was withdrawn before enrolling anyone, so no results exist. Even if it had run, it was a tiny early-phase trial focused on drug levels, not on patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease congenital arteriovenous fistula end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE HEMODIALYSIS VASCULAR ACCESS FAILURE

More trials for these conditions

Other studies related to the condition(s) this trial covers.